| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T10735 | ||||
| Target Name | Histidine decarboxylase | ||||
| Target Type | Clinical Trial |
||||
| Action against Disease Model | Brocresine | Brocresine (NSD-1055) was found to be an effective inhibitor of histidine decarboxylase. With the fairly high dose given (200 mg/kg) the inhibition of histidine decarboxylase was at most 75-85% and quite short-lasting. The DOPA decarboxylase activity, which was not affected by vagal denervation, was inhibited more than 95% by brocresine; this inhibition was longer-lasting. | [537766] | Drug Info | |
| The Effect of Target Knockout, Knockdown or Genetic Variations | Behavioural phenotypes:water maze enhanced;context fear conditioning enhanced; cued fear conditioning enhanced;object recognition task desreased;Plasticity phenotypes: long-termpotentiation enhanced | [537766] | |||
| References | |||||
| Ref 537766 | Effects of brocresine (NSD-1055) and cycloheximide on amino acid decarboxylase activities in gastric mucosa of normal and vagally denervated rats. Br J Pharmacol. 1972 Dec;46(4):688-95. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.